Scan barcode
![Advances in Multiple Sclerosis and Experimental Demyelinating Diseases by](https://558130.bdp32.group/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBCQ0RXQmdFPSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--41026609ff2f1ef1c89ee4345b584b81c3bab25c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RkhKbGMybDZaVjkwYjE5c2FXMXBkRnNIYVFJc0FXa0M5QUU9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--038335c90cf75c275ae4d36968ac417dc4a0a3e3/Advances%20in%20Multiple%20Sclerosis%20and%20Experimental%20Demyelinating%20Diseases.jpg)
362 pages • missing pub info (editions)
ISBN/UID: 9783642437830
Format: Paperback
Language: English
Publisher: Springer
Publication date: 25 September 2014
Description
Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural his...
Community Reviews
Content Warnings
![Advances in Multiple Sclerosis and Experimental Demyelinating Diseases by](https://558130.bdp32.group/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBCQ0RXQmdFPSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--41026609ff2f1ef1c89ee4345b584b81c3bab25c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2RkhKbGMybDZaVjkwYjE5c2FXMXBkRnNIYVFJc0FXa0M5QUU9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--038335c90cf75c275ae4d36968ac417dc4a0a3e3/Advances%20in%20Multiple%20Sclerosis%20and%20Experimental%20Demyelinating%20Diseases.jpg)
362 pages • missing pub info (editions)
ISBN/UID: 9783642437830
Format: Paperback
Language: English
Publisher: Springer
Publication date: 25 September 2014
Description
Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural his...